(amylase, trypsin, lipase). Octreotide increases intestinal transit time and decreases endogenous fluid secretion in the jejunum and ileum, thus increasing the absorption of water and electrolytes. These pharmacological effects of the analogue point to its therapeutic role in a variety of endocrine and gastrointestinal disorders.
Abstract
Somatostatin is a 14 amino acid peptide that inhibits pancreatic exocrine and endocrine secretion. Its clinical application has been limited by its very short half life, necessitating continuous intravenous infusion. Octreotide is an 8 amino acid synthetic analogue of somatostatin that possesses similar pharmacological effects. It has a much longer duration of action, however, and can be given subcutaneously. Both the intravenous and subcutaneous routes of injection of octreotide are well tolerated. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes of a three minute intravenous infusion. Serum concentration increases linearly with dose. Octreotide is distributed rapidly, mainly in the plasma, where it is 65% protein bound. The elimination half life is about 1.5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide. Octreotide inhibits gastroenteropancreatic secretion, especially of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. It also inhibits both release of thyroid stimulating hormone The somatostatin family NATIVE MOLECULAR STRUCTURES Somatostatin is the name given to a family of peptides, the original member of which, somatostatin 14, a tetradecapeptide, was first isolated from ovine hypothalami by Roger Guillemin's group at the Salk Institute, in the course of an unsuccessful search for growth hormone releasing factor. The molecule was shown to inhibit growth hormone release from cultured pituitary cells, and for a while was known variously as growth hormone release inhibiting factor, somatotropin release inhibiting factor, and growth hormone release inhibiting factor, until somatostatin -proposed by the Salk group in a note to the original article -emerged as standard.
The native molecule was found to have a cyclic structure joined by two intramolecular disulphide bonds between the two cysteine residues (Figure) . The linear reduced sequence, however, proved to have the same biological activity as the cyclic form in vitrothat is, the cyclic form was not essential for recognition by specific somatostatin receptors.
A 33 Octreotide has greater pharmacological activity than the native molecule (being at least 20 times more potent in suppressing growth hormone secretion in vivo), is more selective for the inhibition of growth hormone than of insulin, and has a much enhanced duration of action (an elimination half life of 113 minutes compared with the two to three minutes of somatostatin). 32 The synthetic molecule is sufficiently stable even to retain some activity on oral administration, the oral dose required to inhibit growth hormone secretion by 50% being 125 ,ug/kg after one hour. 34 As octreotide is incompletely absorbed after oral administration, investigation of its pharmacokinetic profile used intravenous and subcutaneous injection. Both routes of injection are well tolerated and the incidence of side effects is low. Moreover, bioavailability is similar by both routes of administration. Peak serum concentrations occur within 30 minutes after subcutaneous administration and within four minutes after a short (three minutes) intravenous infusion. Serum concentration of octreotide increases linearly with increasing doses, irrespective of whether the drug is given subcutaneously or intravenously. The average bioavailability of a subcutaneous dose is 1 00% or greater. Distribution is rapid. After a short (three minutes) intravenous infusion, a very rapid distribution phase (tI/2b 0 142-0-210 h) is seen. Once in the blood, octreotide is distributed mainly in the plasma where it is 65% protein bound -mostly to lipoproteins, and to 
administration is approximately 1-5 hours-30 times longer than that of somatostatin. About 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide.
In patients with severe renal impairment, the plasma clearance of octreotide is reduced by 50%.35 This significant reduction points to the presence of a renal component in the elimination of the drug. Thus, when treating patients with renal impairment, the dose of octreotide should be carefully titrated.
Other notable findings reported in the original paper32 were that despite being much more potent than the native molecule, octreotide was better tolerated by laboratory animals, while preliminary trials in humans failed to identify any adverse effects up to the highest infused dose of 50 ,ug/hour (many times higher than the minimal effective dose for inhibiting arginine stimulated growth hormone release). Octreotide appreciably suppresses gastroenteropancreatic secretion, especially that of insulin, glucagon, pancreatic polypeptide, gastric inhibitory polypeptide, and gastrin. This action has been seen both before and after meals, but is less pronounced three hours after a meal, when physiological release of the peptides had already been completed.
Postprandial hyperglycaemia and an increase in fasting plasma glucose have been noted, both probably associated with the decrease in insulin secretion.
Effective suppression of plasma concentrations of insulin and glucagon has been achieved with subcutaneous administration of doses as low as 5 ,ug given 30 minutes before a test meal. Studies have shown that octreotide induces postprandial hyperglycaemia in normal subjects.4445 Patients with non-insulin dependent diabetes mellitus, however, do not experience deterioration in glucose tolerance. 44 Octreotide seems to be a strong inhibitor (80% decrease in healthy subjects) of secretin/ cholecystokinin induced pancreatic enzyme secretion (amylase, trypsin, lipase) and gall bladder contraction.46 This inhibitory effect, however, decreases with time.
Octreotide has been shown to reduce splanchnic blood flow in healthy volunteers and hepatic venous pressure in cirrhotic patients. It has also been shown to accelerate or delay gastric emptying, prolong transit time at moderate to high doses, stimulate motility at low doses, and inhibit gall bladder emptying. Octreotide considerably increases intestinal transit time and endogenous fluid secretion in the jejunum and ileum. As a result, absorption of water and electrolytes is increased.
Octreotide considerably inhibits pentagastrin stimulated gastric acid secretion47 and significantly diminishes exocrine pancreatic function (amylase, trypsin, lipase).
Because of these diverse pharmacological effects, octreotide has been studied in a wide variety of endocrine and gastrointestinal disorders (fistulae, variceal bleeding, diarrhoea, pancreatitis).
